Menlo Therapeutics marching ahead with its Phase 2 clinical trial in Pruritis
Menlo Therapeutics (NASDAQ: MNLO), a late-stage biopharmaceutical company, has announced the completion of enrollment of patients in a crucial phase 2 clinical trial for studying the efficacy and safety of once daily oral serlopitant for the treatment of Chronic Pruritus (itch) of Unknown Origin (CPUO)....
